Markets:

Overview

News

Currencies

International

Treasuries

Rezolute, Inc. - Common Stock (NV) (NQ:RZLT)

9.720 +0.160 (+1.67%)

Official Closing Price Updated: 1:15 PM EST, Nov 28, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Rezolute, Inc. - Common Stock (NV)

< Previous 1 2 3 4 5 6 Next >

Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism

October 11, 2023

From Rezolute, Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Monday ↗

October 02, 2023

On Monday, 369 companies set new 52-week lows.

Via Benzinga

Expert Ratings for Rezolute ↗

September 18, 2023

Via Benzinga

What 4 Analyst Ratings Have To Say About Rezolute ↗

June 28, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

September 15, 2023

Via Benzinga

Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

September 14, 2023

Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023

From Rezolute, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

September 08, 2023

Via Benzinga

Rezolute to Participate in Upcoming Investor Conferences in September

September 06, 2023

From Rezolute, Inc.

Via GlobeNewswire

Short Volatility Alert: Rezolute, Inc. ↗

June 08, 2022

On Tuesday, shares of Rezolute, Inc. (NASDAQ: RZLT) experienced volatile short activity. After the activity, the stock price went down -2.59% to $3.01. The overall sentiment for RZLT has been Bearish.

Via Benzinga

Rezolute's RZ358 Shows Around 75% Reduction In Hypoglycemia Events ↗

May 02, 2022

Via Benzinga

Rezolute And 2 Other Penny Stocks Insiders Are Aggressively Buying ↗

July 07, 2023

The Dow Jones closed lower by over 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism

June 27, 2023

From Rezolute, Inc.

Via GlobeNewswire

Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease

June 01, 2023

Dallas, Texas--(Newsfile Corp. - June 1, 2023) - Stonegate Healthcare Partners (SHP), a healthcare...

Via Newsfile

Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress

May 11, 2023

The Company is poised to commence Phase 3 for RZ358 in the third quarter of calendar year 2023

From Rezolute, Inc.

Via GlobeNewswire

Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema

March 23, 2023

RZ402 is an oral therapy being developed as a potential alternative to anti-vascular growth factor (anti-VEGF) injections into the eye

From Rezolute, Inc.

Via GlobeNewswire

Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert

March 08, 2023

Conference call and webcast to be held on Wednesday, March 22 at 4:30 pm EDT

From Rezolute, Inc.

Via GlobeNewswire

Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress

February 10, 2023

From Rezolute, Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Monday ↗

December 19, 2022

On Monday, 297 companies reached new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

December 16, 2022

Via Benzinga

Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema

December 15, 2022

RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye

From Rezolute, Inc.

Via GlobeNewswire

Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress

November 09, 2022

From Rezolute, Inc.

Via GlobeNewswire

Rezolute to Present at the Jefferies London Healthcare Conference

November 01, 2022

From Rezolute, Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Friday ↗

October 28, 2022

During Friday, 125 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

October 27, 2022

On Thursday, 111 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

October 25, 2022

On Tuesday, 120 companies set new 52-week lows.

Via Benzinga

Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting

October 20, 2022

From Rezolute, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2022 ↗

September 12, 2022

Upgrades

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

September 09, 2022

During Friday's session, 41 companies made new 52-week lows.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2022 ↗

June 15, 2022

Upgrades

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 18, 2022

Gainers Natus Medical (NASDAQ:NTUS) stock rose 28.3% to $33.42 during Monday's pre-market session. The market value of their outstanding shares is at $1.1 billion....

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.